


Stem cell research and regenerative medicine.

Introduction

With the potential to treat a wide range of disease, from organ damage to congenital defects, stem cell research and tissue engineering form the underlying basis of regenerative medicine. Significant advances in the science of skin regeneration, for example, have now made it possible to develop and grow artificial skin grafts in a lab for treatment of burn victims. Other therapeutic applications include the use of stem cells to treat and repair central nervous system diseases such as ischemia and cerebral palsy, cardiovascular diseases, as well as autoimmune diseases including type I diabetes. However, critical research addressing safety concerns, exploring therapeutic function, and assessing mechanisms of action must be completed prior to human adoption. IVIS® optical *in vivo* imaging technology is being widely used to explore stem cell research outcomes in preclinical small animal models, which serve as key test pre-cursors to human clinical trials.

Role for optical imaging

Optical imaging technology has emerged as an established tool to assess efficacy and treatment outcomes of cellbased therapeutics in preclinical models. The IVIS® technology provides vital clues into the viability and behavior of stem cells post transplantation, aiding the prediction of how these cells might behave in humans. A representative sample of stem cell applications, out of hundreds of peer-reviewed citations, is outlined in the following pages. Below is a table showing the various stem cell and progenitor populations that have been imaged on the IVIS imaging platform.



Different stem cell types (Murine/Human)

- Embryonic Stem Cells^{1, 2, 11-56}
- Neural Stem Cells^{17, 18, 57-62}
- Mesenchymal Stem Cells^{4, 5, 63-10}
- Hematopoietic Stem Cells¹⁰²⁻¹⁰⁸
- Muscle Stem Cells^{19, 109-111}
- Adipose-derived Stem Cells^{96, 112, 113}

Progenitor populations

- Different Stem Cell Types (Murine/Human)
- Embryonic Stem Cells^{1, 2, 11-56}
- Neural Stem Cells^{17, 18, 57-62}
- Mesenchymal Stem Cells^{4, 5, 63-101}
- Hematopoietic Stem Cells¹⁰²⁻¹⁰⁸
- Cancer Stem Cells¹²⁶⁻¹³⁸

Labeling strategies

Stem cells are required to be labeled with appropriate bioluminescent or fluorescent reporters to be imaged noninvasively *in vivo*. The following strategies for labeling stem cells with proteins and/or chemical conjugate dyes have previously been used with great success.

Applications

Characterization of stem cell behavior and homing patterns.

Stem cell therapies have been proposed as a putative treatment for arthritis, evidenced by clinical trials currently underway. Pre-clinical models often serve as a 'go' or 'no go' decision point, as potential therapies are often validated and characterized in murine models of disease prior to testing them in human subjects. Two critical points of characterization are their route of administration and their subsequent homing and localization into diseased tissue.

In this study by Sutton et al, featured in the Optics Express, December 2009 issue⁶, mesenchymal stem cells labeled with a fluorescent dye (DiD) were intra-peritoneally injected into athymic polyarthritic rats and shown to preferentially accumulate within arthritic ankle joints *in vivo*. The IVIS platform has served as a vital tool for imaging stem cell viability, migration and targeting of diseased tissue in various models^{6, 29, 60, 72, 139, 140}.




Figure 1: Imaging the accumulation if fluorescent mesenchymal stem cells in arthritic ankle joints (Sutton et al, Opt. Express, 17, p24403, 2009).

Labelling Strategies¹⁻¹⁰

Isolation of stem cells from a transgenic mouse/rat ubiquitously expressing luciferase (e.g. β -actin promoter)

Stable transduction of stem cells with lentiviruses (or non-viral carriers) encoding luciferase/fluorescent reporters

Short-term labeling with fluorescent dyes or nanoparticles

Assessment of safety and therapeutic potential in pre-clinical models

In 2009, the FDA cleared the way for the first clinical trial for embryonic stem cells in the context of spinal cord injury in the US¹⁴¹. Since then numerous such trials have been undertaken in other parts of the world with varying degrees of success. Due to the controversy widely surrounding embryonic stem cells, a new class of reprogrammed cells called ‘induced pluripotent stem cells’ (iPS) have received considerable attention in the past few years since they are derived from adult cell populations and known to retain stem cell properties and function. However, prior to their adoption in human therapy, rigorous testing of their therapeutic efficacy and safety in pre-clinical mouse models is warranted. The IVIS platform plays a key role in such pre-clinical evaluations of iPS and numerous other stem cell types^{11, 13, 24, 37, 54, 58, 72, 78, 81, 96, 117, 121, 142-148}.

The example below is a 2010 report published by Tsuji et al in PNAS¹⁴⁷. The researchers used IVIS imaging to monitor the viability and therapeutic potential of iPS-derived neurospheres in a mouse model of spinal cord injury, suggesting that iPS can ‘safely’ promote locomotor function recovery in injured mouse models.




Figure 2: Imaging survival/viability of bioluminescent iPS-derived neurospheres in a mouse Model of spinal cord injury (Tsuji et al, PNAS. 107, p12704, 2010).

Exploration of molecular pathways and mechanisms of action.

Basic research that outlines key pathways and mechanisms by which stem cells survive, differentiate, migrate, and function are fundamental to our understanding of these cells^{14, 149, 150}. The combination of novel optical reporters, creative molecular biology, and imaging with IVIS technology has facilitated such comprehensive insight into these questions. One vital aspect of hematopoietic stem cell research is identification and definition of their ‘niche,’ a bone marrow microenvironment that both houses and regulates these cells (and their fate).

In a fascinating 2009 report published in Nature, Xie et al⁹ used ex vivo high-resolution microscopy alongside non-invasive (IVIS) imaging to identify and further characterize the stem cell ‘niche,’ its function, and HSC recruitment.




Figure 3: Bioluminescence imaging of hematopoietic stem cell recruitment to their niche *in vivo*, (Xie et al, Nature, 457, p97, 2009).

Identification and validation of complementary stem cell research technologies.

Several research areas including nanotechnology, biomaterials, and cell and tissue engineering complement stem cell research, and are equally invested in the promise of regenerative medicine. Collaborative developments in these fields have yielded biocompatible and biodegradable materials that coupled with growth factors and relevant biomolecules, provide the right ‘scaffold’ or environment to guide stem cells to form functional desired tissues or organs *in vivo*. Often, the survival and function of seeded cells, as well as interactions between the biomaterials and host tissues can be explored using the IVIS system^{113, 116, 144, 151-156}.

In a 2008 report published in PNAS¹⁵⁴, Jennifer Elisseeff’s group at Johns Hopkins University used a combination of chondrocyte-secreted morphogenetic factors and hydrogels to commit mesenchymal stem cells (derived from human embryonic stem cells) into a chondrogenic lineage and eventually form cartilaginous tissue in mice. As seen in the figure below, they relied on IVIS imaging to validate the survival, viability and differentiation of MSCs seeded on a biodegradable polyester scaffold containing hydroxyapatite.




Figure 4: Imaging viability of bioluminescent mesenchymal stem cells seeded on a biodegradable scaffold (Hwang et al, PNAS, 105, p20641, 2008).

Conclusion

In summary, the IVIS optical imaging platform is a valuable tool for stem cell research as it enables spatiotemporal and longitudinal monitoring of stem cell processes, cell viability and homing patterns, and therapeutic function in living animals. These preclinical readouts provide insightful cues to clinicians on the safety and efficacy of stem cell and regenerative medicine therapies to treat human disease.

References

1. Cao F, Drukker M, Lin S, Sheikh AY, Xie X, Li Z, Connolly AJ, Weissman IL, Wu JC. Molecular imaging of embryonic stem cell misbehavior and suicide gene ablation. *Cloning and stem cells.* 2007;9:107-117
2. Cao F, Lin S, Xie X, Ray P, Patel M, Zhang X, Drukker M, Dylla SJ, Connolly AJ, Chen X, Weissman IL, Gambhir SS, Wu JC. *In vivo* visualization of embryonic stem cell survival, proliferation, and migration after cardiac delivery. *Circulation.* 2006;113:1005-1014
3. Duda J, Karimi M, Negrin RS, Contag CH. Methods for imaging cell fates in hematopoiesis. *Methods in molecular medicine.* 2007;134:17-34
4. Spaeth EL, Dembinski JL, Sasser AK, Watson K, Klopp A, Hall B, Andreeff M, Marini F. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. *PLoS ONE.* 2009;4:e4992
5. Spaeth EL, Marini FC. Dissecting mesenchymal stem cell movement: Migration assays for tracing and deducing cell migration. *Methods in molecular biology.* 2011;750:241-259
6. Sutton EJ, Boddington SE, Nedopil AJ, Henning TD, Demos SG, Baehner R, Sennino B, Lu Y, Daldrup-Link HE. An optical imaging method to monitor stem cell migration in a model of immune-mediated arthritis. *Optics express.* 2009;17:24403-24413
7. Sutton EJ, Henning TD, Pichler BJ, Bremer C, Daldrup-Link HE. Cell tracking with optical imaging. *European radiology.* 2008;18:2021-2032
8. Tolar J, Osborn M, Bell S, McElmurry R, Xia L, Riddle M, Panoskaltsis-Mortari A, Jiang Y, McIvor RS, Contag CH. Real-time *in vivo* imaging of stem cells following transgenesis by transposition. *Molecular Therapy.* 2005;12:42-48
9. Xie Y, Yin T, Wiegraebe W, He XC, Miller D, Stark D, Perko K, Alexander R, Schwartz J, Grindley JC, Park J, Haug JS, Wunderlich JP, Li H, Zhang S, Johnson T, Feldman RA, Li L. Detection of functional hematopoietic stem cell niche using real-time imaging. *Nature.* 2009;457:97-101
10. Ushiki T, Kizaka-Kondoh S, Ashihara E, Tanaka S, Masuko M, Hirai H, Kimura S, Aizawa Y, Maekawa T, Hiraoka M. Noninvasive tracking of donor cell homing by near-infrared fluorescence imaging shortly after bone marrow transplantation. *PLoS ONE.* 2010;5
11. Barberi T, Bradbury M, Dincer Z, Panagiotakos G, Soccia ND, Studer L. Derivation of engraftable skeletal myoblasts from human embryonic stem cells. *Nat Med.* 2007;13:642-648
12. Boddington SE, Henning TD, Jha P, Schlieve CR, Mandrusow L, DeNardo D, Bernstein HS, Ritner C, Golovko D, Lu Y, Zhao S, Daldrup-Link HE. Labeling human embryonic stem cell-derived cardiomyocytes with indocyanine green for noninvasive tracking with optical imaging: An fdacompitable alternative to firefly luciferase. *Cell transplantation.* 2010;19:55-65
13. Cao F, van der Bogt K, Sadrzadeh A, Xie X, Sheikh A, Wang H, Connolly A, Robbins R, Wu J. Spatial and temporal kinetics of teratoma formation from murine embryonic stem cell transplantation. *Stem cells and development.* 2007;16:883-892
14. Cao F, Wagner RA, Wilson KD, Xie X, Fu JD, Drukker M, Lee A, Li RA, Gambhir SS, Weissman IL, Robbins RC, Wu JC. Transcriptional and functional profiling of human embryonic stem cell-derived cardiomyocytes. *PLoS ONE.* 2008;3
15. Cao F, Xie X, Gollan T, Zhao L, Narsinh K, Lee RJ, Wu JC. Comparison of gene-transfer efficiency in human embryonic stem cells. *Mol Imaging Biol.* 2009

16. Chan KM, Raikwar SP, Zavazava N. Strategies for differentiating embryonic stem cells (esc) into insulin-producing cells and development of non-invasive imaging techniques using bioluminescence. *Immunologic research*. 2007;39:261-270
17. D aadi MM, Li Z, Arac A, Grueter BA, Sofilos M, Malenka RC, Wu JC, Steinberg GK. Molecular and magnetic resonance imaging of human embryonic stem cell-derived neural stem cell grafts in ischemic rat brain. *Molecular therapy : the journal of the American Society of Gene Therapy*. 2009;17:1282-1291
18. D aadi MM, Li Z, Arac A, Grueter BA, Sofilos M, Malenka RC, Wu JC, Steinberg GK. Molecular and magnetic resonance imaging of human embryonic stem cell-derived neural stem cell grafts in ischemic rat brain. *Mol Ther*. 2009;17:1282-1291
19. D arabi R, Santos FN, Filareto A, Pan W, Koene R, Rudnicki MA, Kyba M, Perlingeiro RC. Assessment of the myogenic stem cell compartment following transplantation of pax3/pax7-induced embryonic stem cell derived progenitors. *Stem cells*. 2011;29:777-790
20. D uan Y, Catana A, Meng Y, Yamamoto N, He S, Gupta S, Gambhir SS, Zern MA. Differentiation and enrichment of hepatocyte-like cells from human embryonic stem cells *in vitro* and *in vivo*. *Stem Cells*. 2007;25:3058-3068
21. E vseenko D, Schenke-Layland K, Dravid G, Zhu Y, Hao QL, Scholes J, Wang XC, Maclellan WR, Crooks GM. Identification of the critical extracellular matrix proteins that promote human embryonic stem cell assembly. *Stem cells and development*. 2009;18:919-928
22. Hendry SL, 2nd, van der Bogt KE, Sheikh AY, Arai T, Dylla SJ, Drukker M, McConnell MV, Kutschka I, Hoyt G, Cao F, Weissman IL, Connolly AJ, Pelletier MP, Wu JC, Robbins RC, Yang PC. Multimodal evaluation of *in vivo* magnetic resonance imaging of myocardial restoration by mouse embryonic stem cells. *The Journal of thoracic and cardiovascular surgery*. 2008;136:1028-1037 e1021
23. Huang NF, Niizuma H, De A, Gambhir SS, Cooke JP. Embryonic stem cell-derived endothelial cells for treatment of hindlimb ischemia. *J Vis Exp*. 2009
24. Huang NF, Niizuma H, Peter C, De A, Natkunam Y, Fleissner F, Li Z, Rollins MD, Wu JC, Gambhir SS, Cooke JP. Embryonic stem cell-derived endothelial cells engraft into the ischemic hindlimb and restore perfusion. *Arteriosclerosis, thrombosis, and vascular biology*. 2010;30:984-991
25. Hwang NS, Varghese S, Lee HJ, Zhang Z, Ye Z, Bae J, Cheng L, Elisseff J. *In vivo* commitment and functional tissue regeneration using human embryonic stem cell-derived mesenchymal cells. *Proceedings of the National Academy of Sciences of the United States of America*. 2008;105:20641-20646
26. Kodama M, Tsukamoto K, Yoshida K, Aoki K, Kanegasaki S, Quinn G. Embryonic stem cell transplantation correlates with endogenous neurogenin 3 expression and pancreas regeneration in streptozotocin-injured mice. *J Histochem Cytochem*. 2009;57:1149-1158
27. Le U, Bom H, Moon S, Park K, Han H, Lee H, Song H, Min J. *In vivo* imaging of embryonic stem cell implantation into rat corpus cavernosum by using optical imaging system. *J Nucl Med*. 2007;48:327P
28. Lee AS, Tang C, Cao F, Xie X, van der Bogt K, Hwang A, Connolly AJ, Robbins RC, Wu JC. Effects of cell number on teratoma formation by human embryonic stem cells. *Cell cycle (Georgetown, Tex)*. 2009; 8:2608-2612
29. Lee AS, Wu JC. Imaging of embryonic stem cell migration *in vivo*. *Methods in molecular biology*. 2011;750:101-114
30. Li Z, Suzuki Y, Huang M, Cao F, Xie X, Connolly AJ, Yang PC, Wu JC. Comparison of reporter gene and iron particle labeling for tracking fate of human embryonic stem cells and differentiated endothelial cells in living subjects. *Stem Cells*. 2008
31. Li Z, Wilson KD, Smith B, Kraft DL, Jia F, Huang M, Xie X, Robbins RC, Gambhir SS, Weissman IL, Wu JC. Functional and transcriptional characterization of human embryonic stem cell-derived endothelial cells for treatment of myocardial infarction. *PLoS ONE*. 2009;4
32. Li Z, Wu JC, Sheikh AY, Kraft D, Cao F, Xie X, Patel M, Gambhir SS, Robbins RC, Cooke JP, Wu JC. Differentiation, survival, and function of embryonic stem cell derived endothelial cells for ischemic heart disease. *Circulation*. 2007;116:I46-54

33. Linehan JL, Tian X, Morris JK, Kaufman DS. Improved analysis of hematopoietic engraftment by non-invasive *in vivo* bioluminescent imaging of transplanted human embryonic stem cell-derived hematopoietic cells. *Blood*. 2005;106:370A
34. Moon SH, Kim JS, Park SJ, Lee HJ, Do JT, Chung HM. A system for treating ischemic disease using human embryonic stem cell-derived endothelial cells without direct incorporation. *Biomaterials*. 2011;32:6445-6455
35. Narsinh KH, Cao F, Wu JC. Application of reporter gene imaging for studying human embryonic stem cells in living subjects. *Viral applications of green fluorescent protein*. 2009;13-32.
36. Priddle H, Grabowska A, Morris T, Clarke PA, McKenzie AJ, Sottile V, Denning C, Young L, Watson S. Bioluminescence imaging of human embryonic stem cells transplanted *in vivo* in murine and chick models. *Cloning and stem cells*. 2009;11:259-267
37. Raikwar SP, Zavazava N. Spontaneous *in vivo* differentiation of embryonic stem cell-derived pancreatic endoderm-like cells corrects hyperglycemia in diabetic mice. *Transplantation*. 2011;91:11-20
38. Sun N, Lee A, Wu JC. Long term non-invasive imaging of embryonic stem cells using reporter genes. *Nature protocols*. 2009;4:1192-1201
39. Suzuki Y, Zhang S, Kundu P, Yeung A, Robbins R, Yang P. *In vitro* comparison of the biological effects of three transfection methods for magnetically labeling mouse embryonic stem cells with ferumoxides. *Magnetic Resonance in Medicine*. 2007;57:1173-1179
40. Swijnenburg RJ, Schrepfer S, Cao F, Pearl JI, Xie X, Connolly AJ, Robbins RC, Wu JC. *In vivo* imaging of embryonic stem cells reveals patterns of survival and immune rejection following transplantation. *Stem cells and development*. 2008;17:1023-1029
41. Swijnenburg RJ, Schrepfer S, Govaert JA, Cao F, Ransohoff K, Sheikh AY, Haddad M, Connolly AJ, Davis MM, Robbins RC, Wu JC. Immunosuppressive therapy mitigates immunological rejection of human embryonic stem cell xenografts. *Proceedings of the National Academy of Sciences of the United States of America*. 2008;105:12991-12996
42. Takeshita F, Kodama M, Yamamoto H, Ikarashi Y, Ueda S, Teratani T, Yamamoto Y, Tamatani T, Kanegasaki S, Ochiya T, Quinn G. Streptozotocin- induced partial beta cell depletion in nude mice with out hyperglycaemia induces pancreatic morphogenesis in transplanted embryonic stem cells. *Diabetologia*. 2006;49:2948-2958
43. Teratani T, Yamamoto H, Aoyagi K, Sasaki H, Asari A, Quinn G, Terada M, Ochiya T. Direct hepatic fate specification from mouse embryonic stem cells. *Hepatology (Baltimore, Md)*. 2005;41:836-846
44. Tian X, Hexum MK, Penchev VR, Taylor RJ, Shultz LD, Kaufman DS. Bioluminescent imaging demonstrates transplanted human embryonic stem cell-derived cd34(+) cells preferentially develop into endothelial cells. *Stem Cells*. 2009
45. Tian X, Woll PS, Morris JK, Linehan JL, Kaufman DS. Hematopoietic engraftment of human embryonic stem cell-derived cells is regulated by recipient innate immunity. *Stem Cells*. 2006;2005-0340
46. Wang S, Hu C, Zhu J. Transcriptional silencing of a novel hprt reporter locus during *in vitro* differentiation of mouse embryonic stem cells *Molecular Biology of the Cell*. 2007;18:669-677
47. Wilber A, Linehan JL, Tian X, Woll PS, Morris JK, Belur LR, McIvor RS, Kaufman DS. Efficient and stable transgene expression in human embryonic stem cells using transposon-mediated gene transfer. *Stem Cells*. 2007;25:2919-2927
48. Wilson K, Yu J, Lee A, Wu JC. *In vitro* and *in vivo* bioluminescence reporter gene imaging of human embryonic stem cells. *J Vis Exp*. 2008
49. Wilson KD, Huang M, Wu JC. Bioluminescence reporter gene imaging of human embryonic stem cell survival, proliferation, and fate. *Methods in molecular biology* (Clifton, N.J. 2009;574:87-103
50. Woll PS, Grzywacz B, Tian X, Marcus RK, Knorr DA, Verneris MR, Kaufman DS. Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent *in vivo* antitumor activity. *Blood*. 2009;113:6094-6101

51. Wu J, Spin J, Cao F, Lin S, Xie X, Gheysens O, Chen I, Sheikh A, Robbins R, Tsalenko A. Transcriptional profiling of reporter genes used for molecular imaging of embryonic stem cell transplantation. *Physiological genomics*. 2006;25:29
52. Wu JC, Li Z, Xu L, Giffard RG, Wu J, Cooke JP. Transplantation of embryonic stem cell derived endothelial cells promote functional recovery after cerebral ischemia. *Circulation*. 2006;114:627
53. Wu JC FCSDXXEKNCSGSMAJCMBEWW. Proteomic analysis of reporter genes for molecular imaging of transplanted embryonic stem cells. *PROTEOMICS*. 2006;9999:NA
54. Xie X, Cao F, Sheikh AY, Li Z, Connolly AJ, Pei X, Li RK, Robbins RC, Wu JC. Genetic modification of embryonic stem cells with vegf enhances cell survival and improves cardiac function. *Cloning and stem cells*. 2007;9:549-563
55. Yamada M, Gurney P, Chung J, Kundu P, Drukker M, Smith A, Weissman I, Nishimura D, Robbins R, Yang P. Manganese guided cellular mri of human embryonic stem cell and human bone marrow stromal cell viability. *Magnetic Resonance in Medicine*. 2009;62:1047-1054
56. Yu J, Huang NF, Wilson KD, Velotta JB, Huang M, Li Z, Lee A, Robbins RC, Cooke JP, Wu JC. Nachrs mediate human embryonic stem cell derived endothelial cells: Proliferation, apoptosis, and angiogenesis. *PLoS ONE*. 2009;4:e7040
57. Chen H, Ma H, Sytwu H, Wang H, Chen C, Liu S, Chen C, Chen H, Wang C. Neural stem cells secrete factors that promote auditory cell proliferation via a leukemia inhibitory factor signaling pathway. *Journal of Neuroscience Research*. 2010;88:3308-3318
58. D aadi MM, Davis AS, Arac A, Li Z, Maag AL, Bhatnagar R, Jiang K, Sun G, Wu JC, Steinberg GK. Human neural stem cell grafts modify microglial response and enhance axonal sprouting in neonatal hypoxic-ischemic brain injury. *Stroke; a journal of cerebral circulation*. 2010;41:516-523
59. Okada S, Ishii K, Yamane J, Iwanami A, Ikegami T, Katoh H, Iwamoto Y, Nakamura M, Miyoshi H, Okano HJ, Contag CH, Toyama Y, Okano H. *In vivo* imaging of engrafted neural stem cells: Its application in evaluating the optimal timing of transplantation for spinal cord injury. *Faseb J*. 2005
60. Pendharkar AV, Chua JY, Andres RH, Wang N, Gaeta X, Wang H, De A, Choi R, Chen S, Rutt BK, Gambhir SS, Guzman R. Biodistribution of neural stem cells after intravascular therapy for hypoxic-ischemia. *Stroke; a journal of cerebral circulation*. 2010;41:2064-2070
61. Sher F, van Dam G, Boddeke E, Copray S. Bioluminescence imaging of olig2-neural stem cells reveals improved engraftment in a demyelination mouse model. *Stem Cells*. 2009;27:1582-1591
62. Zhao D, Najbauer J, Garcia E, Metz MZ, Glackin CA, Kim SU, Aboody KS. Novel neural stem cell-mediated tumor selective gene therapy for breast cancer metastases. *Molecular Therapy*. 2009;17:S137
63. Andreeff M, Dembinski J, Hall BM, Studeny M, Ling X, Cabreira-Hansen M, Kate Sasser A, McQueen T, Lang F, Marini FC. Mesenchymal stem cells selectively engraft into tumor stroma and produce potent antitumor proteins in situ. *Blood*. 2006;108:109A
64. Battula V, Evans K, Hollier B, Shi Y, Marini F, Ayyanan A, Wang R, Briskin C, Guerra R, Andreeff M. Epithelial mesenchymal transition derived cells exhibit multi lineage differentiation potential similar to mesenchymal stem cells. *Stem Cells*. 2010;28:1435-1445
65. Beksac M, Kuzu I, Ozdemir M, Ayten M, Dalva K, Ucnullkan D, Kilicnull E, Attar A, Kanpolat Y. Tracking of donor type green fluorescent and luciferase positive marrow mononuclear or mesenchymal stem cells in postmortem spinal cord histopathological sections for determination of regeneration in a spinal cord injury model. *Haematologica*. 2009;94:66
66. Cao XC, Wang B, Cong Y, Yan F. Human umbilical cord mesenchymal stem cell transplantation ameliorates inflammation in a mouse model of colitis. *Gastroenterology*. 2009;136:A406-A407
67. Chan J, Kumar S, Fisk NM. First trimester embryo-fetoscopic and ultra sound-guided fetal blood sampling for ex vivo viral transduction of cultured human fetal mesenchymal stem cells. *Human reproduction (Oxford, England)*. 2008;23:2427-2437
68. Chanda D, Isayeva T, Kumar S, Hensel JA, Sawant A, Ramaswamy G, Siegal GP, Beatty MS, Ponnazhagan S. Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in prostate cancer bone metastasis. *Clin Cancer Res*. 2009;15:7175-7185

69. Chen WH, Liu HY, Lo WC, Wu SC, Chi CH, Chang HY, Hsiao SH, Wu CH, Chiu WT, Chen BJ, Deng WP. Intervertebral disc regeneration in an ex vivo culture system using mesenchymal stem cells and platelet-rich plasma. *Biomaterials*. 2009;30:5523-5533
70. D'elise T, Peter C, Fedak PW, Doyle T, Reichensperner H, Zimmermann WH, Eschenhagen T, Stein W, Wu JC, Robbins RC, Schrepfer S. Hepatocyte growth factor or vascular endothelial growth factor gene transfer maximizes mesenchymal stem cell-based myocardial salvage after acute myocardial infarction. *Circulation*. 2009;120:S247-254
71. Geroni E, Gallo B, Casazza S, Musio S, Bonanni I, Pedemonte E, Mantegazza R, Frassoni F, Mancardi G, Pedotti R, Uccelli A. Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. *Annals of neurology*. 2007;61:219-227
72. Granero-Molto F, Weis JA, Miga MI, Landis B, Myers TJ, O'Rear L, Longobardi L, Jansen ED, Mortlock DP, Spagnoli A. Regenerative effects of transplanted mesenchymal stem cells in fracture healing. *Stem Cells*. 2009
73. Guillot P, Abass O, Bassett J, Shefelbine S, Bou-Gharios G, Chan J, Kurata H, Williams G, Polak J, Fisk N. Intrauterine transplantation of human fetal mesenchymal stem cells from first-trimester blood repairs bone and reduces fractures in osteogenesis imperfecta mice. *Blood*. 2008;111:1717
74. Guillot P, Cook H, Pusey C, Fisk N, Harten S, Moss J, Shore I, Bou-Gharios G. Transplantation of human fetal mesenchymal stem cells improves glomerulopathy in a collagen type Ialpha2-deficient mouse. *The Journal of pathology*. 2008;214:627-636
75. Hakkarainen T, Särkioja M, Lehenkari P, Miettinen S, Ylikomi T, Suuronen R, Desmond R, Kanerva A, Hemminki A. Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors. *Human Gene Therapy*. 2007;18:627-641
76. Hata N, Shinojima N, Gumin J, Yong R, Marini F, Andreeff M, Lang FF. Platelet-derived growth factor bb mediates the tropism of human mesenchymal stem cells for malignant gliomas. *Neurosurgery*. 2010;66:144-156; discussion 156-147
77. Joo SY, Cho KA, Jung YJ, Kim HS, Park SY, Choi YB, Hong KM, Woo SY, Seoh JY, Ryu KH. Bioimaging to monitor the *in vivo* distribution of infused mesenchymal stem cells: In a mouse model of graft versus host disease. *Cell Biology International*. 2010
78. Kanazawa H, Fujimoto Y, Teratani T, Iwasaki J, Kasahara N, Negishi K, Tsuruyama T, Uemoto S, Kobayashi E. Bone marrow-derived mesenchymal stem cells ameliorate hepatic ischemia reperfusion injury in a rat model. *PLoS ONE*. 2011;6:e19195
79. Kidd S, Spaeth E, Dembinski JL, Dietrich M, Watson K, Klopp A, Battula L, Weil M, Andreeff M, Marini FC. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using *in vivo* bioluminescence imaging. *Stem Cells*. 2009
80. Klopp AH, Spaeth EL, Dembinski JL, Woodward WA, Munshi A, Meyn RE, Cox JD, Andreeff M, Marini FC. Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. *Cancer research*. 2007;67:11687-11695
81. Kumar S, Wan C, Ramaswamy G, Clemens TL, Ponnazhagan S. Mesenchymal stem cells expressing osteogenic and angiogenic factors synergistically enhance bone formation in a mouse model of segmental bone defect. *Mol Ther*. 2010
82. Lien CY, Chih-Yuan Ho K, Lee OK, Blunn GW, Su Y. Restoration of bone mass and strength in glucocorticoid-treated mice by systemic transplantation of cxcr4 and cbfa-1 co-expressing mesenchymal stem cells. *J Bone Miner Res*. 2009;24:837-848
83. Ling X, Marini F, Konopleva M, Schober W, Shi Y, Burks J, Clise-Dwyer K, Wang R, Zhang W, Yuan X. Mesenchymal stem cells overexpressing ifn-inhibit breast cancer growth and metastases through stat3 signaling in a syngeneic tumor model. *Cancer Microenvironment*. 2010;3:1-13
84. Love Z, Wang F, Dennis J, Awadallah A, Salem N, Lin Y, Weisenberger A, Majewski S, Gerson S, Lee Z. Imaging of mesenchymal stem cell transplant by bioluminescence and pet. *J Nucl Med*. 2007; 48:2011-2020

85. Mader EK, Maeyama Y, Lin Y, Butler GW, Russell HM, Galanis E, Russell SJ, Dietz AB, Peng KW. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. *Clin Cancer Res.* 2009;15:7246-7255
86. Marini F, Dembinski J, Studeny M, Zompetta C, Andreeff M. Mesenchymal stem cells as delivery systems for cancer therapy: Evaluation of tropism and efficacy. *Molecular Therapy.* 2005;11:S173
87. Marini FC, Dembinski JL, Studeny M, Ling X, Zompetta C, Andreeff M. Mesenchymal stem cells selectively engraft into tumor stroma and confer potent antitumor activity. *Cyotherapy.* 2006;8:282
88. Martinello-Wilks R, Larsen SR, Tiffen JC, Bailey CG, Rasko JEJ. Mesenchymal stem cells as suicide gene therapy vehicles for organ-confined and metastatic prostate cancer (pca). *Blood.* 2007;110:369B
89. Min JJ AY, Moon S, Kim YS, Park JE, Kim SM, Le UN, Wu JC, Joo SY, Hong MH, Yang DH, Jeong MH, Song CH, Jeong YH, Yoo KY, Kang KS, Bom HS. *In vivo* bioluminescence imaging of cord blood derived mesenchymal stem cell transplantation into rat myocardium. *Annals of Nuclear Medicine.* 2006;20:165-170
90. Morikawa S, Mabuchi Y, Kubota Y, Nagai Y, Niibe K, Hiratsu E, Suzuki S, Miyauchi-Hara C, Nagoshi N, Sunabori T, Shimmura S, Miyawaki A, Nakagawa T, Suda T, Okano H, Matsuzaki Y. Prospective identification, isolation, and systemic transplantation of multipotent mesenchymal stem cells in murine bone marrow. *The Journal of experimental medicine.* 2009;206:2483-2496
91. Park JS, Na K, Woo DG, Yang HN, Kim JM, Kim JH, Chung HM, Park KH. Non-viral gene delivery of DNA polyplexed with nanoparticles transfected into human mesenchymal stem cells. *Biomaterials.* 2010;31:124-132
92. Schrepfer S, Deuse T, Lange C, Katzenberg R, Reichenspurner H, Robbins R, Pelletier M. Simplified protocol to isolate, purify, and culture expand mesenchymal stem cells. *Stem cells and development.* 2007;16:105-108
93. Toegel F, Yang Y, Zhang P, Hu Z, Westenfelder C. Bioluminescence imaging to monitor the *in vivo* distribution of administered mesenchymal stem cells in acute kidney injury. *American journal of physiology.* 2008
94. Tolar J, Nauta AJ, Osborn MJ, Panoskaltsis Mortari A, McElmurry RT, Bell S, Xia L, Zhou N, Riddle M, Schroeder TM, Westendorf JJ, McLvor RS, Hogendoom PCW, Szuhai K, Oseth L, Hirsch B, Yant SR, Kay MA, Peister A, Prockop DJ, Fibbe WE, Blazar BR. Sarcoma derived from cultured mesenchymal stem cells. *Stem Cells.* 2006;2005-0620
95. Uchibori R, Okada T, Ito T, Urabe M, Mizukami H, Kume A, Ozawa K. Retroviral vector-producing mesenchymal stem cells for targeted suicide cancer gene therapy. *The journal of gene medicine.* 2009;11:373-381
96. van der Bogt KE, Schrepfer S, Yu J, Sheikh AY, Hoyt G, Govaert JA, Velotta JB, Contag CH, Robbins RC, Wu JC. Comparison of transplantation of adipose tissue- and bone marrow-derived mesenchymal stem cells in the infarcted heart. *Transplantation.* 2009;87:642-652
97. Wang F, Dennis JE, Awadallah A, Solchaga LA, Molter J, Kuang Y, Salem N, Lin Y, Tian H, Kolthammer JA, Kim Y, Love ZB, Gerson SL, Lee Z. Transcriptional profiling of human mesenchymal stem cells transduced with reporter genes for imaging. *Physiological genomics.* 2008
98. Wang H, Cao F, De A, Cao Y, Contag C, Gambhir SS, Wu JC, Chen X. Trafficking mesenchymal stem cell engraftment and differentiation intumor-bearing mice by bioluminescence imaging. *Stem Cells.* 2009;27:1548-1558
99. Yeh SP, Lo WJ, Chang YC, Tsai WJ, Lin CL, Liao YM. Tumor homing activity of bone marrow-derived mesenchymal stem cell is highly various among different tumors on syngeneic mouse model using real-time *in vivo* imaging technique. *Blood.* 2009;114
100. Yong RL, Shinojima N, Fueyo J, Gumin J, Vecil GG, Marini FC, Bogler O, Andreeff M, Lang FF. Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus delta24-rgd to human gliomas. *Cancer research.* 2009;69:8932-8940

101. Zachos T, Diggs A, Weisbrode S, Bartlett J, Bertone A. Mesenchymal stem cell-mediated gene delivery of bone morphogenetic protein-2 in an articular fracture model. *Mol Ther.* 2007;15:1543-1550
102. Bastianutto C, Mian A, Symes J, Mocanu J, Alajez N, Sleep G, Shi W, Keating A, Crump M, Gospodarowicz M, Medin J, Minden M, Liu FF. Local radiotherapy induces homing of hematopoietic stem cells to the irradiated bone marrow. *Cancer research.* 2007;67:10112-10116
103. BitMansour A, Burns SM, Traver D, Akashi K, Contag CH, Weissman IL, Brown JM. Myeloid progenitors protect against invasive aspergillosis and pseudomonas aeruginosa infection following hematopoietic stem celltransplantation. *Blood.* 2002;100:4660-4667
104. Gao J, Li Y, Lu S, Wang M, Yang Z, Yan X, Zheng Y. Enhanced *in vivo* motility of human umbilical cord blood hematopoietic stem/progenitor cells introduced via intra-bone marrow injection into xenotransplanted nod/scid mouse. *Experimental hematology.* 2009;37:990-997
105. Lin Y, Molter J, Lee Z, Gerson SL. Bioluminescence imaging of hematopoietic stem cell repopulation in murine models. *Methods in molecular biology* (Clifton, N.J. 2008;430:295-306
106. Wang X, Rosol M, Ge S, Petersen D, Kohn DB, Nelson MD, Crooks GM. Vivo bioluminescence imaging reveals the kinetics of human hematopoietic stem cell engraftment. *Blood.* 2003;102:939a
107. Wang X, Rosol M, Ge S, Peterson D, McNamara G, Pollack H, Kohn DB, Nelson MD, Crooks GM. Dynamic tracking of human hematopoietic stem cell engraftment using *in vivo* bioluminescence imaging. *Blood.* 2003;102:3478-3482
108. Zakrzewski JL, Kochman AA, Lu SX, Terwey TH, Kim TD, Hubbard VM, Muriglan SJ, Suh D, Smith OM, Grubin J, Patel N, Chow A, Cabrera-Perez J, Radhakrishnan R, Diab A, Perales MA, Rizzuto G, Menet E, Pamer EG, Heller G, Zuniga-Pflucker JC, Alpdogan O, van den Brink MR. Adoptive transfer of tcell precursors enhances t-cell reconstitution after allogeneic hematopoietic stem cell transplantation. *Nat Med.* 2006;12:1039-1047
109. Asakura A, Hirai H, Kablar B, Morita S, Ishibashi J, Piras BA, Christ AJ, Verma M, Vineretsky KA, Rudnicki MA. Increased survival of muscle stem cells lacking the myoD gene after transplantation into regenerating skeletal muscle. *Proceedings of the National Academy of Sciences of the United States of America.* 2007;104:16552-16557
110. Nishijo K, Hosoyama T, Bjornson CR, Schaffer BS, Prajapati SI, Bahadur AN, Hansen MS, Blandford MC, McCleish AT, Rubin BP, Epstein JA, Rando TA, Capecchi MR, Keller C. Biomarker system for studying muscle, stem cells, and cancer *in vivo*. *Faseb J.* 2009
111. Sacco A, Doyonnas R, Kraft P, Vitorovic S, Blau HM. Selfrenewal and expansion of single transplanted muscle stem cells. *Nature.* 2008;456:502-506
112. Bai X, Yan Y, Song YH, Seidensticker M, Rabinovich B, Metzele R, Bankson JA, Vykovkal D, Alt E. Both cultured and freshly isolated adipose tissue-derived stem cells enhance cardiac function after acute myocardial infarction. *European heart journal.* 2009
113. Chang EI, Bonillas RG, El-Ftesi S, Chang EI, Ceradini DJ, Vial IN, Chan DA, Michaels Jt, Gurtner GC. Tissue engineering using autologous microcirculatory beds as vascularized bioscaffolds. *Faseb J.* 2008
114. Dickson PV, Hamner JB, Burger RA, Garcia E, Ouma AA, Kim SU, Ng CY, Gray JT, Aboody KS, Danks MK, Davidoff AM. Intravascular administration of tumor tropic neural progenitor cells permits targeted delivery of interferon-beta and restricts tumor growth in a murine model of disseminated neuroblastoma. *J Pediatr Surg.* 2007;42:48-53
115. Sims TL, Jr., Hamner JB, Bush RA, Williams RF, Zhou J, Kim SU, Aboody KS, Danks MK, Davidoff AM. Neural progenitor cell-mediated delivery of interferon beta improves neuroblastoma response to cyclophosphamide. *Annals of surgical oncology.* 2008;15:3259-3267
116. Kim KL, Han DK, Park K, Song SH, Kim JY, Kim JM, Ki HY, Yie SW, Roh CR, Jeon ES, Kim DK, Suh W. Enhanced dermal wound neovascularization by targeted delivery of endothelial progenitor cells using an rgd-g-plla scaffold. *Biomaterials.* 2009;30:3742-3748

117. Nguyen Huu S, Oster M, Uzan S, Chareyre F, Aractingi S, Khosrotehrani K. Maternal neoangiogenesis during pregnancy partly derives from fetal endothelial progenitor cells. *Proceedings of the National Academy of Sciences of the United States of America*. 2007;104:1871-1876
118. Highfill SL, Kelly RM, O'Shaughnessy MJ, Zhou Q, Xia L, Panoskalsis-Mortari A, Taylor PA, Tolar J, Blazar BR. Multipotent adult progenitor cells can suppress graft-versus-host disease via prostaglandin e2 synthesis and only if localized to sites of allopriming. *Blood*. 2009;114:693-701
119. Tolar J, O'Shaughnessy MJ, Panoskalsis-Mortari A, McElmurry RT, Bell S, Riddle M, McIvor RS, Yant SR, Kay MA, Krause D, Verfaillie CM, Blazar BR. Host factors that impact the biodistribution and persistence of multipotent adult progenitor cells. *Blood*. 2006;2005-2008-3289
120. Tolar J, Wang X, Braunlin E, McElmurry RT, Nakamura Y, Bell S, Xia L, Zhang J, Hu Q, Panoskalsis-Mortari A, Zhang J, Blazar BR. The host immune response is essential for the beneficial effect of adult stem cells after myocardial ischemia. *Experimental hematology*. 2007;35:682-690
121. Li S, Tu Q, Zhang J, Stein G, Lian J, Yang PS, Chen J. Systemically transplanted bone marrow stromal cells contributing to bone tissue regeneration. *Journal of cellular physiology*. 2008;215:204-209
122. Abdel-Azim H, Zhu Y, Hollis R, Wang X, Ge S, Hao QL, Smbatyan G, Kohn DB, Rosol M, Crooks GM. Expansion of multipotent and lymphoidcommitted human progenitors through intracellular dimerization of mpl. *Blood*. 2008;111:4064-4074
123. Cao YA, Wagers AJ, Karsunky H, Zhao H, Reeves R, Wong RJ, Stevenson DK, Weissman IL, Contag CH. Heme oxygenase-1 deficiency leads to disrupted response to acute stress in stem cells and progenitors. *Blood*. 2008;112:4494-4502
124. Cheng JC, Kinjo K, Judelson D, Chang J, Wu WS, Schmid I, Shankar DB, Kasahara N, Stripecke R, Bhatia R, Landaw EM, Sakamoto KM. Creb is a critical regulator of normal hematopoiesis and leukemogenesis. *Blood*. 2007;110:101-108
125. Kim WI, Wiesner SM, Largaespada DA. Vav promoter-tta conditionaltransgene expression system for hematopoietic cells drives high level expression in developing b and t cells. *Experimental hematology*. 2007;35:1231-1239
126. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, Oh EY, Gaber MW, Finklestein D, Allen M, Frank A, Bayazitov IT, Zakharenko SS, Gajjar A, Davidoff A, Gilbertson RJ. A perivascular niche for brain tumor stem cells. *Cancer cell*. 2007;11:69-82
127. Charafe-Jauffret E, Ginestier C, Iovino F, Tarpin C, Diebel M, Esterni B, Houvenaeghel G, Extra JM, Bertucci F, Jacquemier J, Xerri L, Dontu G, Stassi G, Xiao Y, Barsky SH, Birnbaum D, Viens P, Wicha MS. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. *Clin Cancer Res*. 2010;16:45-55
128. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F, Dutcher J, Brown M, Viens P, Xerri L, Bertucci F, Stassi G, Dontu G, Birnbaum D, Wicha MS. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. *Cancer research*. 2009;69:1302-1313
129. Chen L, Shen R, Ye Y, Pu XA, Liu X, Duan W, Wen J, Zimmerer J, Wang Y, Liu Y, Lasky LC, Heerema NA, Perrotti D, Ozato K, Kuramochi-Miyagawa S, Nakano T, Yates AJ, Carson IW, Lin H, Barsky SH, Gao JX. Precancerous stem cells have the potential for both benign and malignant differentiation. *PLoS ONE*. 2007;2(1):e362
130. Conway AE, Lindgren A, Galic Z, Pyle AD, Wu H, Zack JA, Pellegrini M, Teitel MA, Clark A. A pluripotency and self-renewal program controls the expansion of genetically unstable cancer stem cells in pluripotent stem cell derived tumors. *Stem Cells*. 2008;26:270-279
131. E yler CE, Wu Q, Yan K, Macswords JM, Chandler-Militello D, Misuraca KL, Lathia JD, Forrester MT, Lee J, Stamler JS, Goldman SA, Bredel M, McLendon RE, Sloan AE, Hjelmeland AB, Rich JN. Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. *Cell*. 2011;146:53-66

132. Garzia L, Andolfo I, Cusanelli E, Marino N, Petrosino G, De Martino D, Esposito V, Galeone A, Navas L, Esposito S, Gargiulo S, Fattet S, Donofrio V, Cinalli G, Brunetti A, Vecchio LD, Northcott PA, Delattre O, Taylor MD, Iolascon A, Zollo M. Microrna-199b-5p impairs cancer stem cells through negative regulation of hes1 in medulloblastoma. *PLoS ONE*. 2009;4:e4998
133. Ghods AJ, Irvin D, Liu G, Yuan X, Abdulkadir IR, Tunici P, Konda B, Wachsmann-Hogiu S, Black KL, Yu JS. Spheres isolated from 9L gliosarcoma rat cell line possess chemoresistant and aggressive cancer stem-like cells. *Stem Cells*. 2007;25:1645-1653
134. Hart LS, El-Deiry WS. Invincible, but not invisible: Imaging approaches toward *in vivo* detection of cancer stem cells. *J Clin Oncol*. 2008;26:2901-2910
135. Kang Y. Analysis of cancer stem cell metastasis in xenograft animal models. *Cancer stem cells*. 2008;7:19.
136. Kang Y. Analysis of cancer stem cell metastasis in xenograft animal models. *Methods in molecular biology* (Clifton, N.J. 2009;568:7-19
137. Murohashi M, Hinohara K, Kuroda M, Isagawa T, Tsuji S, Kobayashi S, Umezawa K, Tojo A, Aburatani H, Gotoh N. Gene set enrichment analysis provides insight into novel signalling pathways in breast cancer stem cells. *British journal of cancer*. 2010;102:206-212
138. Thorne SH, Contag CH. Integrating the biological characteristics of oncolytic viruses and immune cells can optimize therapeutic benefits of cell-based delivery. *Gene therapy*. 2008
139. Reumers V, Deroose CM, Krylyshkina O, Nuyts J, Geraerts M, Mortelmans L, Gijsbers R, Van den Haute C, Debysen Z, Baekelandt V. Noninvasive and quantitative monitoring of adult neuronal stem cell migration in mouse brain using bioluminescence imaging. *Stem Cells*. 2008;26:2382-2390
140. Steiner D, Gelovani J, Savoldo B, Robinson SN, Decker WK, Brouard N, Najjar A, Xing D, Yang H, Li S, Marini F, Zweidler-McKay PA, Bolland CM, Shpall EJ, Dotti G, Simmons PJ. Noninvasive bioluminescent imaging demonstrates long-term multilineage engraftment of ex vivo-expanded CD34-selected umbilical cord blood cells. *Stem Cells*. 2009
141. Pollack A. F.D.A. Approves a stem cell trial. *New York Times*. 2009
142. Cheng K, Li TS, Malliaras K, Davis DR, Zhang Y, Marban E. Magnetic targeting enhances engraftment and functional benefit of iron-labeled cardiosphere-derived cells in myocardial infarction. *Circulation research*. 2010;106:1570-1581
143. Lee SH, Hao E, Savinov AY, Geron I, Strongin AY, Itkin-Ansari P. Human beta-cell precursors mature into functional insulin-producing cells in an immunoisolation device: Implications for diabetes cell therapies. *Transplantation*. 2009;87:983-991
144. Levenberg S, Rouwkema J, Macdonald M, Garfein ES, Kohane DS, Darland DC, Marini R, van Blitterswijk CA, Mulligan RC, D'Amore PA, Langer R. Engineering vascularized skeletal muscle tissue. *Nat Biotechnol*. 2005;23:879-884
145. Martinez-Fernandez A, Nelson TJ, Yamada S, Reyes S, Alekseev AE, Perez-Terzic C, Ikeda Y, Terzic A. iPS programmed without c-myc yield proficient cardiogenesis for functional heart chimerism. *Circulation research*. 2009;105:648-656
146. Ransohoff KJ, Wu JC. Advances in cardiovascular molecular imaging for tracking stem cell therapy. *Thromb Haemost*. 2010;104:13-22
147. Tsuji O, Miura K, Okada Y, Fujiyoshi K, Mukaino M, Nagoshi N, Kitamura K, Kumagai G, Nishino M, Tomisato S, Higashi H, Nagai T, Katoh H, Kohda K, Matsuzaki Y, Yuzaki M, Ikeda E, Toyama Y, Nakamura M, Yamanaka S, Okano H. Therapeutic potential of appropriately evaluated safe-induced pluripotent stem cells for spinal cord injury. *Proceedings of the National Academy of Sciences of the United States of America*. 2010;107:12704-12709
148. van der Bogt KE, Sheikh AY, Schrepfer S, Hoyt G, Cao F, Ransohoff KJ, Swijnenburg RJ, Pearl J, Lee A, Fischbein M, Contag CH, Robbins RC, Wu JC. Comparison of different adult stem cell types for treatment of myocardial ischemia. *Circulation*. 2008;118:S121-129

149. Chimenti I, Smith RR, Li TS, Gerstenblith G, Messina E, Giacomello A, Marban E. Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice. *Circulation research*. 2010
150. Leucht P, Kim JB, Amasha R, James AW, Girod S, Helms JA. Embryonic origin and hox status determine progenitor cell fate during adult bone regeneration. *Development (Cambridge, England)*. 2008;135:2845-2854
151. Cao F, Sadrzadeh Rafie AH, Abilez OJ, Wang H, Blundo JT, Pruitt B, Zarins C, Wu JC. *In vivo* imaging and evaluation of different biomaterials for improvement of stem cell survival. *J Tissue Eng Regen Med*. 2007;1:465-468
152. Fujita A, Migita M, Ueda T, Ogawa R, Fukunaga Y, Shimada T. Hematopoiesis in regenerated bone marrow within hydroxyapatite scaffold. *Pediatric research*. 2010;68:35-40
153. G iannoni P, Scaglione S, Daga A, Ilengo C, Cilli M, Quarto R. Short-time survival and engraftment of bone marrow stromal cells in an ectopic model of bone regeneration. *Tissue Eng Part A*. 2009
154. Hwang DW, Jang SJ, Kim YH, Kim HJ, Shim IK, Jeong JM, Chung JK, Lee MC, Lee SJ, Kim SU, Kim S, Lee DS. Real-time *in vivo* monitoring of viable stem cells implanted on biocompatible scaffolds. *European journal of nuclear medicine and molecular imaging*. 2008
155. Logeart-Avramoglou D, Oudina K, Bourguignon M, Delpierre L, Nicola MA, Bensidhoum M, Arnaud E, Petite H. *In vitro* and *in vivo* bioluminescent quantification of viable stem cells in engineered constructs. *Tissue engineering*. 2009
156. Martinez EC, Wang J, Gan SU, Singh R, Lee CN, Kofidis T. Ascorbic acid improves embryonic cardiomyoblast cell survival and promotes vascularization in potential myocardial grafts *in vivo*. *Tissue Eng Part A*. 2010



revvity